CPC technology class · G21
G21G - Conversion Of Chemical Elements
Conversion of chemical elements; radioactive sources. 629 US utility patents granted 2015–2025, with the leading assignees and year-by-year grant trajectory.
- 629
- US patents granted
- #5/8
- in G21
- 7.0%
- G21 class share
- +35%
- 5-yr velocity
The verdict
According to USPTO PatentsView, Conversion Of Chemical Elements ranks #515 of 670 CPC technology areas - 629 US patents granted since 2015, with recorded grant volume up 35% over five years.
- #515
- of 670 CPC technology areas
- 629
- US patents granted, 2015–2025
- Curium Us
- leading assignee (25)
- +35%
- grant velocity, last 5 yrs
How G21G's grant cadence moved
Between 2020–2024, G21G recorded 315 grants versus 234 in 2015–2019 (+35% equal-window velocity). Across complete years, output peaked in 2020 at 75 grants and bottomed in 2015 at 42 (+79% peak-over-trough). Lead assignee Curium US LLC holds 4.0% of the class ; the top three share 9.7%.
Leaderboard read
G21G concentration, lead at 4.0%
Curium US LLC leads this historical grant record at 4.0% of G21G - us corporation assignees hold 61% of class grants (196 of 319). Figures describe granted US utility patents in this CPC subclass, not current investment or legal strength.
- Leader's share
- 4.0%
- Top three share
- 9.7%
- Lead over #2
- 6
25 of 629 grants
of the class's recorded grants
more grants than Bracco Diagnostics Inc.
Where G21G sits inside G21
Among 8 subclasses in G21 (Nuclear PHYSICS; Nuclear Engineering), G21G ranks #5 and holds 7.0% of the parent class's 8,981 recorded grants. Sibling chips below are the other subclasses in the same parent class, not the nationwide volume/lead-share peers further down.
Rising assignees active in G21G
Company-wide grant multiples (2022–2024 vs 2019–2021) among assignees with ≥5 patents in this subclass. Growth is company-wide; class patent counts are subclass-specific.
- #1 Shine Technologies, LLC 16x 0 → 16 company-wide · 11 in G21G
- #2 Bwxt Isotope Technology Group, Inc. 12x 0 → 12 company-wide · 10 in G21G
- #3 Jubilant Draximage Inc. 3.00x 4 → 12 company-wide · 9 in G21G
- #4 Neutron Therapeutics LLC 2.00x 2 → 4 company-wide · 5 in G21G
- #5 Orano MED 1.50x 2 → 3 company-wide · 6 in G21G
G21G grants by year, peak 2020 (75)
US utility-patent grants per year in G21G, 2015–2025 - recent five years are up 35% versus 2015–2019.
Who leads G21G?
The 12 most active assignees in Conversion OF Chemical ELEMENTS; Radioactive Sources - wider bars mean more grants
- Curium Us
Curium US LLC
25 patents
- Bracco Diagnostics
Bracco Diagnostics Inc.
19 patents
- Westinghouse Electric
Westinghouse Electric Company LLC
17 patents
- Neuboron Medtech
Neuboron Medtech Ltd.
17 patents
- Ge-hitachi Nuclear…
GE-Hitachi Nuclear Energy Americas LLC
15 patents
- Qsa Global
QSA Global Inc.
13 patents
- Shine
Shine Technologies, LLC
11 patents
- Bwxt Isotope…
Bwxt Isotope Technology Group, Inc.
10 patents
- Framatome 9
Framatome
9 patents
- Jubilant Draximage 9
Jubilant Draximage Inc.
9 patents
- Ge Healthcare 8
GE Healthcare Limited
8 patents
- Adelphi Technology 8
Adelphi Technology, Inc.
8 patents
What this shows Curium Us is the most active filer in G21G, holding 25 of the 629 patents in this class. Concentration at the top signals how contestable this technology area is for new entrants.
View data table
| Rank | Company | Patents in G21G |
|---|---|---|
| #1 | Curium US LLC | 25 |
| #2 | Bracco Diagnostics Inc. | 19 |
| #3 | Westinghouse Electric Company LLC | 17 |
| #4 | Neuboron Medtech Ltd. | 17 |
| #5 | GE-Hitachi Nuclear Energy Americas LLC | 15 |
| #6 | QSA Global Inc. | 13 |
| #7 | Shine Technologies, LLC | 11 |
| #8 | Bwxt Isotope Technology Group, Inc. | 10 |
| #9 | Framatome | 9 |
| #10 | Jubilant Draximage Inc. | 9 |
| #11 | GE Healthcare Limited | 8 |
| #12 | Adelphi Technology, Inc. | 8 |
| #13 | Mallinckrodt Nuclear Medicine LLC | 7 |
| #14 | Texas Thorium LLC | 7 |
| #15 | Ion Beam Applications | 6 |
| #16 | Orano MED | 6 |
| #17 | Neutron Therapeutics LLC | 5 |
| #18 | Mallinckrodt LLC | 4 |
| #19 | General Atomics | 4 |
| #20 | Nihon Medi-physics Co., Ltd. | 4 |
Footprint here vs. claim strategy
Each dot is a leading G21G assignee, placed by how many patents it holds in this class (horizontal) against its company-wide average claims per patent (vertical) - a read on whether the class is led by broad-but-shallow filers or focused deep-claim players.
Classes near G21G's 629-grant footprint
Nationwide nearest neighbors for G21G (#515 of 670 by volume ; lead share 4.0%) - not the G21 parent-class siblings above.
Questions about G21G
Which company holds the most patents in G21G?
Which G21G assignees grew fastest recently?
How does G21G compare inside parent class G21?
What to do with this data
G21G in context - here's where to go next.
- Curium US LLC leads G21G with 25 grants in this class. See full portfolio
- G21G ranks #515 of 670 by grant volume among all tracked CPC technology areas. See the ranking
- Inside parent class G21, the largest sibling subclass is G21K with 3,019 grants. Explore G21K
Figures reflect USPTO PatentsView grant data through 2026-05-15; pending applications not yet granted are not counted.
Methodology - G21G figures are USPTO PatentsView granted-utility totals for this subclass (629 grants in the tracked window).
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.